Understanding the stroma of pancreatic cancer: Co-evolution of the microenvironment with epithelial carcinogenesis

Journal of Pathology

Volumn 231, Issue 1, 2013, Pages 4-7

  Erkan, Mert ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Evolution; Hypoxia; Microenvironment; Pancreatic stellate cells; Stroma; Therapy resistance

Indexed keywords

GEMCITABINE; IPI 926 03; K RAS PROTEIN; PLATELET DERIVED GROWTH FACTOR; SARIDEGIB; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER STEM CELL; CARCINOGENESIS; CELL DEATH; CELL INTERACTION; CELL INVASION; CELL MOTION; CELL PROLIFERATION; DRUG DELIVERY SYSTEM; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATIC STELLATE CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; STROMA; TISSUE PRESSURE; TUMOR MICROENVIRONMENT;

EID: 84885187627     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4213     Document Type: Review

References (25)

1. Winter JM, Brennan MF, Tang LH, et al. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol 2012; 19: 169-175.
2. Hong SM, Park JY, Hruban RH, et al. Molecular signatures of pancreatic cancer. Arch Pathol Lab Med 2011; 135: 716-727.
3. Streit S, Michalski CW, Erkan M, et al. Confirmation of DNA microarray-derived differentially expressed genes in pancreatic cancer using quantitative RT-PCR. Pancreatology 2009; 9: 577-582.
4. Lohr M, Kloppel G, Maisonneuve P, et al. Frequency of Kras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a metaanalysis. Neoplasia 2005; 7: 17-23.
5. Perez-Mancera PA, Guerra C, Barbacid M, et al.. What we have learned about pancreatic cancer from mouse models. Gastroenterology 2012; 142: 1079-1092.
6. Appels NM, Beijnen JH, Schellens JH. Development of farnesyl transferase inhibitors: a review. Oncologist 2005; 10: 565-578.
7. Kullmann F, Hartmann A, Stohr R, et al. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy. Oncology 2011; 81: 3-8.
8. Erkan M, Reiser-Erkan C, Michalski CW, et al. The impact of the activated stroma on pancreatic ductal adenocarcinoma biology and therapy resistance. Curr Mol Med 2012; 12: 288-303.
9. Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2012; 62: 112-120.
10. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324: 1457-1461.
11. Provenzano PP, Cuevas C, Chang AE, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012; 21: 418-429.
12. Conroy T, Gavoille C, Adenis A. Metastatic pancreatic cancer: old drugs, new paradigms. Curr Opin Oncol 2011; 23: 390-395.
13. Erkan M, Adler G, Apte MV, et al. StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut 2012; 61: 172-178.
14. Erkan M, Michalski CW, Rieder S, et al. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol 2008; 6: 1155-1161.
15. Apte MV, Wilson JS. Dangerous liaisons: pancreatic stellate cells and pancreatic cancer cells. J Gastroenterol Hepatol 2012; 27(suppl 2): 69-74.
16. Erkan M. The role of pancreatic stellate cells in pancreatic cancer. Pancreatology 2013; 13: 106-109.
17. Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011; 17: 320-329.
18. Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer 2012; 12: 487-493.
19. Kadaba R, Birke H, Wang J, et al. Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes. J Pathol 2013; 230: 107-117.
20. Boucher Y, Leunig M, Jain RK. Tumor angiogenesis and interstitial hypertension. Cancer Res 1996; 56: 4264-4266.
21. Brown LF, Dvorak AM, Dvorak HF. Leaky vessels, fibrin deposition, and fibrosis: a sequence of events common to solid tumors and to many other types of disease. Am Rev Respir Dis 1989; 140: 1104-1107.
22. Erkan M, Weis N, Pan Z, et al. Organ-, inflammation- and cancerspecific transcriptional fingerprints of pancreatic and hepatic stellate cells. Mol Cancer 2010; 9: 88.
23. Masamune A, Shimosegawa T. Pancreatic stellate cells-multifunctional cells in the pancreas. Pancreatology 2013; 13: 102-105.
24. Michalski CW, Gorbachevski A, Erkan M, et al. Mononuclear cells modulate the activity of pancreatic stellate cells, which in turn promote fibrosis and inflammation in chronic pancreatitis. J Transl Med 2007; 5: 63.
25. Ripoche J. Blood platelets and inflammation: their relationship with liver and digestive diseases. Clin Res Hepatol Gastroenterol 2011; 35: 353-357.